The Food and Drug Administration is preparing to launch a study of how well consumers understand the lengthy list of safety risks listed in drug advertisements — and whether there are so many warnings that their eyes glaze over.

But the study, and related work at the FDA, have irked the drug industry and spurred critics of direct-to-consumer drug advertisements to argue the agency should be doing more.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Drug ads don’t belong on TV, newspapers, magazines, or social media. Period. It just raises costs to consumers. Exactly how many patoents need Keytruda or Opdivo anyway?

    • I agree completely. First, by the time they are through you’ve been convinced that any good they do is offset by the side effects and they also give false hope to many individuals, plus then every patient wants the newest most expensive drug for their condition whether it works or not. Do away with them altogether.

    • The commercial that always gives me a chuckle is the one that warns against taking the drug if you have multiple endocrineal neoplasia type 2. How many people actually know what that is? Ask your doctor whether STATNEWS is right for you!

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy